- Conditions
- Rheumatoid Arthritis
- Interventions
- Active Stimulation, Sham Stimulation, Baricitinib, Background Treatment
- Device · Drug
- Lead sponsor
- Galvani Bioelectronics
- Industry
- Eligibility
- 22 Years to 75 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 12
- States / cities
- Anniston, Alabama • Covina, California • Whittier, California + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 13,959
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Jaw, Edentulous, Partially
- Interventions
- ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm), ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting
- Device
- Lead sponsor
- Dentsply Sirona Implants and Consumables
- Industry
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2022
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Acute Kidney Injury
- Interventions
- SBI-101, Sham
- Biological · Device
- Lead sponsor
- Sentien Biotechnologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Allentown, Pennsylvania
- Conditions
- Brain Metastases From HER2 and Breast Cancer, Advanced HER2-positive Breast Cancer
- Interventions
- ARRY-380 Twice Daily Dosage, ARRY-380 Once Daily, Trastuzumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- HIV Infections
- Interventions
- Tetanus toxoid, Hepatitis A Vaccine (Inactivated)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 24 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Alhambra, California • Long Beach, California + 18 more
- Conditions
- Pancreatic Cancer
- Interventions
- Cyclophosphamide, Cyclophosphamide Pill, GVAX Pancreas Vaccine
- Drug · Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer
- Interventions
- MEM-288 Intratumoral Injection, Nivolumab, Docetaxel
- Biological · Drug
- Lead sponsor
- Memgen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Durham, North Carolina
- Conditions
- HIV Infections, Hepatitis C
- Interventions
- highly active antiretroviral therapy (HAART)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Primary Myelofibrosis, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis
- Interventions
- RO7490677, Ruxolitinib
- Biological · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 7 more
- Conditions
- Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome
- Interventions
- Azacitidine, Seclidemstat
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hematological Malignancies
- Interventions
- KPG-818
- Drug
- Lead sponsor
- Kangpu Biopharmaceuticals, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 10
- States / cities
- Sacramento, California • Plantation, Florida • Louisville, Kentucky + 7 more
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Selinexor, Fludarabine, Cytarabine, methotrexate/hydrocortisone/cytarabine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 24 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Palo Alto, California • Chicago, Illinois + 4 more
- Conditions
- Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma
- Interventions
- Fulvestrant, Repotrectinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma, Follicular
- Interventions
- Ofatumumab, Bendamustine infusion, Ofatumumab and Bendamustine infusions (Arm A), Bendamustine infusion (Arm B)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Beverly Hills, California • Palm Springs, California + 15 more
- Conditions
- Neutropenia, Sarcoma
- Interventions
- filgrastim, amifostine trihydrate, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, topotecan hydrochloride, vincristine sulfate, conventional surgery, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 30 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1995
- U.S. locations
- 43
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 35 more
- Conditions
- Advanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- TAS-114, S-1
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Loma Linda, California • Gainesville, Florida • Cleveland, Ohio + 3 more
- Conditions
- HIV/AIDS
- Interventions
- Storytelling Narrative Intervention
- Combination Product
- Lead sponsor
- University of Massachusetts, Boston
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Penile Carcinoma
- Interventions
- Dostarlimab, Niraparib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Houston, Texas
- Conditions
- Opioid-Related Disorders, Chronic Pain
- Interventions
- Buprenorphine, Hydromorphone, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Relapsed or Refractory Follicular Lymphoma
- Interventions
- Mosunetuzumab, Lenalidomide, Rituximab, Tociluzumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 17
- States / cities
- Duarte, California • Atlanta, Georgia • Fort Wayne, Indiana + 13 more
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Midostaurin, Placebo, Chemotherapy
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Portland, Oregon
- Conditions
- Renal Cell Carcinoma
- Interventions
- lenvatinib, everolimus
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 8
- States / cities
- Duarte, California • Whittier, California • Miami, Florida + 5 more
- Conditions
- Cystic Fibrosis
- Interventions
- Triple combination therapy
- Drug
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Ulcerative Colitis
- Interventions
- Not listed
- Lead sponsor
- Janssen Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 16
- States / cities
- Murrieta, California • Rialto, California • Ventura, California + 13 more